
TARGETING CANCER
AT THE ROOT
To develop best-in-class innovative molecules for patients
OUR MISSION
To develop best-in-class innovative molecules for patients
We are developing best-in-class innovative molecules for patients battling rare and difficult to treat cancers with a high unmet medical need by targeting cancer at the root.

OUR SCIENCES
We are leveraging our world leading expertise in cancer cell biology, molecular modelling and medicinal chemistry to identify and drug novel targets in oncology
ABOUT TNA THERAPEUTICS
Developing Potential
Treatments for a Variety
of Tumor Types
TNA Therapeutics Inc. is early stage pharmaceutical company focused on developing TNAT-101, a safe and well-tolerated first-in-class, oral agent that inhibits BCL3. By reducing and in most cases preventing further metastasis

OUR HISTORY
2
PATENTS
$14M
INVESTED
3
OFFICES
1.5kg
GMP DRUG MANUFACTURED
ABOUT TNA THERAPEUTICS
Partnering, Collaborating & Combining Towards the Future
TNA Therapeutics will grow through partnerships and collaborations
-
Grants received such as the Alderley Park/CRUK/InnovateUK award recently provided to the company
-
Partnership with Adlai Nortye in China to develop pelareorep for metastatic breast cancer

INNOVATE UK

ALDERLEY PARK

ADLAI NORTYE

CANCER RESEARCH